Last reviewed · How we verify
Ceftriaxon
At a glance
| Generic name | Ceftriaxon |
|---|---|
| Also known as | Ceftriaxone (ATC code J01DD04), Ceftriaxone |
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Target | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Adult Gonococcal Conjunctivitis
- Bacterial arthritis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial meningitis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Chancroid
- Disseminated Gonococcal Infection
- E. Coli Joint Infection
- E. Coli Osteomyelitis
- E. Coli Peritonitis
- E. Coli Septic Arthritis
- Endometritis
- Enterobacter Osteomyelitis
- Enterobacter Pneumonia
Common side effects
- Elevations of alanine aminotransferase (ALT)
- Elevations of aspartate aminotransferase (AST)
- Diarrhea/loose stools
- Leukopenia
- Rash
- Elevations of BUN
- Pain, induration and tenderness
- Granulocytopenia
- Injection site pain
- Blood creatinine increased
- Coagulopathy
- Genital fungal infection
Serious adverse events
- Anaphylaxis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis (Lyell's syndrome)
- Agranulocytosis
- Seizures
- Acute renal failure
- Bronchospasm
- Allergic pneumonitis
- Kernicterus
- Crystalline material precipitation (neonates)
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- PK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftriaxon CI brief — competitive landscape report
- Ceftriaxon updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Vaudois portfolio CI